Pharmabiz
 

VTU Technology, Boehringer Ingelheim expand global microbial technology collaboration

Vienna, AustriaFriday, April 29, 2016, 11:00 Hrs  [IST]

VTU Technology, the Austrian protein expression expert announced the expansion of their global technology collaboration with Boehringer Ingelheim RCV GmbH & Co. KG, a global research-driven pharmaceutical company.

After successful completion of a first development program, followed by prolongation of the collaboration, Boehringer Ingelheim is now widening the technological scope. The collaboration includes the advancement of Boehringer Ingelheim’s E. coli expression platform in addition to the competitive optimization of Pichia pastoris platforms for the production of biopharmaceuticals.

“The intensification of our joint development program underlines the potential and capabilities of VTU Technology and our skilled and experienced team. This collaboration gives VTU certain access rights to Boehringer Ingelheim’s proprietary E. coli expression technologies broadening VTU’s range of services”, said Dr. Thomas Purkarthofer, head of business development of VTU Technology.

“Widening our cooperation with VTU Technology increases our capabilities and resources for the development of microbial based biopharmaceutical processes. Including E. coli based expression systems to the existing successful cooperation will strengthen our technology leadership and add significant potential for both companies“, said Georg Klima, executive director Process Science Austria at Boehringer Ingelheim.

 
[Close]